anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Objective: To evaluate the mid-term efficacy of one-stage unicompartmental knee arthroplasty (UKA) combined with anterior cruciate ligament (ACL) reconstruction in the treatment of medial compartment osteoarthritis (OA) with ACL deficiency. Methods: Retrospective cohort study. The clinical data of 13 patients (14 knees) who underwent UKA with ACL reconstruction for knee medial compartment OA combined with ACL deficiency in Wangjing Hospital of China Academy of Chinese Medical Sciences from January 2012 to January 2020 were retrospective analyzed. A 1∶1 proportioning study was conducted with 13 patients (14 knees) who underwent UKA due to medial compartment OA with intact ACL during the same period. The matching conditions were the same gender, age, surgical side, anesthesia method, comorbidities, and imaging lesions. There were 26 patients (28 knees) in the two groups, including 6 males (6 knees) and 20 females (22 knees), aged (58.9±4.2) years. The range of motion (ROM) and Oxford Knee Score (OKS) were used to evaluate the knee joint function at the last follow-up. The anteroposterior, lateral and axial X-ray films of the knee joint and the weight-bearing full-length X-ray films of the lower limbs were taken during follow-up. The hip knee ankle (HKA) angle, the posterior slope angle (PSA) of tibial prosthesis, and the anterior tibial translation (ATT) were recorded and compared between the two groups. The progression of lateral compartment OA, prosthesis loosening, and dislocation were evaluated. The mid-term follow-up clinical efficacy of the two surgical methods was compared, and the etiology of the patients was analyzed to verify the clinical efficacy and patient selection of one-stage UKA combined with ACL reconstruction. Results: The follow-up time of the two groups was (7.14±2.45) years. At the last follow-up, there was no significant difference in joint ROM between the combined group and the UKA group (120.90°±2.95° vs 122.29°±3.22°, P=0.260). There was no significant difference in OKS score between the two groups [(42.50±1.99) vs (43.21±2.26), P=0.380]. There was no significant difference in HKA angle and ATT distance between the two groups before operation (both P>0.05). At the last follow-up, the results were better than those before operation, and the differences were statistically significant (both P<0.05). At the last follow-up, there was no significant difference in HKA Angle between the combined group and the simple group (177.79°±1.25 ° vs 177.86°±1.29°, P=0.880). Tibial prosthesis PSA and ATT distance were not significantly different between the two groups [(4.57°±0.94° vs 4.50°±1.34°and (0.21±0.89) mm vs (0.14±1.35) mm, both P>0.05)]. There was no prosthesis loosening and obvious progression of lateral compartment OA in both groups at the last follow-up. Conclusion: For young patients with medial compartment OA secondary to ACL deficiency, UKA combined with ACL reconstruction is recommended, it can obtain good mid-term results.
Patients in the sham Virtual Reality group will receive the same brand of head mounted device (Oculus Quest 2), but will only have access to sham content. Both groups will receive standard of care linaclotide treatment 290 mcg.
Disclosed is Bifidobacterium lactis TY-S01 for relieving constipation. The strain is deposited with the China General Microbiological Culture Collection Center (CGMCC) on November 27, 2020, and assigned the accession number CGMCC No.21255. Through an animal validation experiment, it is confirmed that TY-S01 can relieve loperamide hydrochloride-induced constipation in mice, shorten the first defecation time of melena, increase water content in feces, accelerate intestinal peristalsis, and effectively inhibit damage of small intestinal villi. In addition, the TY-S01 significantly elevates levels of acetic acid, propionic acid, butyric acid, isobutyric acid, and valeric acid in feces of mice. Finally, the TY-S01 may relieve constipation by elevating SCFAs levels of the intestinal tract. The Bifidobacterium lactis TY-S01 provided in the present invention may increase the content of short-chain fatty acid in the intestinal tract of the mice with constipation, so that the constipation can be relieved. As the Bifidobacterium lactis TY-S01 has no side effects and desirable effects, a new treatment idea can be provided for patients with constipation.
The invention discloses preparation methods of a cymipristone solid preparation. A method 1 comprises the following steps: dissolving cymipristone in a solvent to obtain a drug-containing solution, then evenly mixing auxiliary materials with the drug-containing solution, and performing wet granulation, wherein, the solvent is an organic solvent or an aqueous solution containing more than 85% of an organic solvent by mass percent. A method 2 comprises the following steps: dissolving the cymipristone in an acid solution containing an acidulant to obtain a drug-containing acid solution, then evenly mixing the auxiliary materials with the drug-containing acid solution, and performing wet granulation. The invention further discloses the cymipristone solid preparation prepared by the methods. The preparation methods disclosed by the invention avoid the defects such as serious pollution, great loss and serious potential safety hazard caused by mechanical pulverization, and the methods are simple and feasible in operation and have a high safety factor, thus being applicable to industrial production. The cymipristone solid preparation prepared by the methods has the advantages of excellent leaching property, better stability and better content uniformity.
When we look at the literature, the Laughter Yoga practice is held between 2 weeks and 10 weeks, once a week, 5 times a week, 2 weeks and lasting approximately 25-45 minutes. In this study, the intervention will be implemented within 8 weeks. To the women who constitute the intervention group; After giving short-term self-care training in Menopause for 8 weeks, relaxation will be applied after the practice of Laughter yoga, which starts with breathing exercises, warm-up exercises, childlike games and has different exercises in each session. The research will be carried out in the Famagusta Municipality Development Academy, in a bright hall where women can take a U shape, everyone will be face to face, and will not be disturbed during the application.
The present invention relates to a hemlock parsley preparation for treating thromboangitis obliterans, and a prescription thereof. The concrete prescription comprises: 15 grams of leech pulverized for later use, 100 to 150 grams of honeysuckle, 20 grams of dandelion, 15 grams of forsythiae, 1 gram of rhinoceros horn powder, 15 grams of hemlock parsley, 15 grams of angelica, 30 to 60 grams of red peony root, 12 grams of peach kernel, 15 grams of safflower, 30 grams of red sage root, 10 grams of frankincense, 10 grams of myrrh, 1 gram of rice shell, 10 grams of common prism rhizome, 10 grams of zedoary, 30 grams of radix rehmanniae root, 20 grams of figwort, 10 grams of orange peel, 15 grams of sinomenium acutum and 6 grams of liquorice. Water is added to the materials, and the mixed liquid is boiled with strong fire, and then is decocted and concentrated with mild fire. Physic liquor decocted for three times is merged into one. Effective ingredients extracted from medicines in the prescription can be made into decoction, pills, powder or other preparation types. Leech powder is taken with the physic liquor for multiple times during taking the physic liquor. The hemlock parsley preparation can be used for treating wet and dry angitis; in the concrete treatment process, auxiliary medicines are also matched to better enhance curative effect and heal thromboangitis obliterans as soon as possible.
This app provides daily suggestions for overcoming depressed mood and allows users to track their mood, using the 0-9 scale available for all three apps. In the first app session, participants are given a general education about depression and its known causes and consequences. Participants are told that to overcome mood problems, they must engage in one mood improvement strategy a day and that the app will suggest one to try each day.
The present invention generally relates to compositions, such as gels comprising steroids. In certain aspects, the steroids are modified such that they can form gels, e.g., when complexed to metal ions. In some cases, the steroids form fibers, such as nanofibers, within the gel. For instance, in one set of embodiments, a steroid may be relatively hydrophobic, and/or modified to include a phosphate moiety that is able to complex to metal ions to form the gel. In some cases, such gels may be administered to a subject, e.g., through injection. Other aspects of the invention are generally directed to methods of making or using such gels, kits comprising such gels, or the like.
The study is an open-label, prospective, parallel-group, randomized, controlled medical device clinical trial, conducted in two centers. The two arms of the trial consist of patients randomized to the new device group and to the TOT group. According to this distribution, one group will be subjected to the operation with the new device, and the other group will be subjected to the operation with a commercially available TOT. Primary objective: Evaluation of the effectiveness of using the new device in the surgical treatment of urinary incontinence. Secondary objectives: Evaluation of the effects of the new device use on patients' quality of life, treatment satisfaction, and sexual functions, as well as assessment of safety. The study includes evaluation of the progress employing objective (pad weight, number of incontinence episodes, urodynamic tests) and subjective tests (questionnaires, diaries) during the 12 months follow-up period.
BACKGROUND: Hepatitis B virus (HBV) infection is a public health problem that seriously threatens human health. This study aimed to investigate the clinical significance of glutathione peroxidase 4(GPX4) in the occurrence and development of chronic hepatitis B (CHB).
METHODS: A total of 169 participants including 137 patients with CHB and 32 healthy controls (HCs) were recruited. We detected the expression of GPX4 and stimulator of interferon genes (STING) in peripheral blood mononuclear cells (PBMCs) by real-time quantitative polymerase chain reaction (RT-qPCR). The methylation level of GPX4 gene promoter in PBMCs was detected by TaqMan probe-based quantitative methylation-specific PCR (MethyLight). Enzyme-linked immunosorbent assay (ELISA) was performed to detect the serum levels of GPX4, IFN-β, oxidative stress (OS) related molecules, and pro-inflammatory cytokines.
RESULTS: The expression levels of GPX4 in PBMCs and serum of CHB patients were lower than those of HCs, but the methylation levels of GPX4 promoter were higher than those of HCs, especially in patients at the immune tolerance phase. STING mRNA expression levels in PBMCs and serum IFN-β levels of patients at the immune activation phase and reactivation phase of CHB were higher than those at other clinical phases of CHB and HCs. GPX4 mRNA expression level and methylation level in PBMCs from patients with CHB had a certain correlation with STING and IFN-β expression levels. In addition, the methylation level of the GPX4 promoter in PBMCs from patients with CHB was correlated with molecules associated with OS and inflammation.
CONCLUSIONS: GPX4 may play an important role in the pathogenesis and immune tolerance of CHB, which may provide new ideas for the functional cure of CHB.
Subjects will be dosed for 28 days. A thin layer of ointment will be applied to all areas designated for treatment.
The Korean herbal medicine is a complex extract of medicinal herbs prescribed by a Korean medicine doctor who has completed specialized education to diagnose the health condition and symptoms of patients with post-traffic accident syndromes. This treatment is known to relieve the post-accident syndromes and improve health. However, there are no studies examining the efficacy of Korean herbal medicine alone.

So, the investigators will conduct a randomized controlled trials to verify the efficacy and safety of Korean herbal medicine. From July, 2021 to May, 2022, the investigators recruited 40 patients who are suffered from post-accident syndromes with the numeric rating scale(NRS) over 5. For experimental group(the Korean herbal medicine treatment group, n=20), the investigators conducted Korean medicine treatment for 4 weeks(28 days), and for control group(the Non-Korean herbal medicine treatment group, n=20), just Korean medical treatment(acupuncture, pharmacoacupuncture, cupping, and chuna) has been conducted. For these two groups, the investigators compared NRS, Impact of Event Scale-Revised-Korean(IES-R-K), 5-level EuroQol 5-dimension(EQ-5D-5L), Short-Form-12 Health Survey version2(SF-12 v2), and Patient Global Impression of Change(PGIC).
This study will assess the feasibility of a randomized control study designed to remotely deliver a breath control and guided mindfulness exercise to individuals experiencing post-concussion symptoms of anxiety or depression. Participants will be randomized into one of the study arms after they have met eligibility criteria and have given informed consent. Study arm interventions include a 20-minute paced breathing (breath control) exercise, a 20-minute guided mindfulness exercise, and a sham control arm that incorporates a minimal instruction 20-minute quiet sitting meditation exercise. The participant is asked to complete their assigned intervention daily for a period of eight weeks and to complete weekly and biweekly follow-up questionnaires. The questionnaires will include the Rivermead Post-Concussion Syndrome Questionnaire (RPQ) and the Positive Affect Negative Affect Survey Short Form (PANAS) completed weekly, the General Anxiety and Depression questionnaire (GAD-7) and the Patient Health Questionnaire (PHQ-9) completed biweekly. These questionnaires will be completed prior to a participant commencing the study (pre-test measure), at weekly intervals throughout the study (at end of week), and at the conclusion of the 8-week study (post-test measure). At the conclusion of the study participants will be asked to complete the Treatment Acceptability / Adherence Scale (TAAS), a measure used to assess the acceptability of the intervention from the point of view of the participant. All participant outcome measures, and intervention tracking questionnaires will be administered through a secure internet user-input interface.
1. A method for delivering an aerosolized active agent to the lungs of a human patient, comprising delivering the aerosolized active agent formulation at a flow resistance for an initial time period wherein the flow resistance is a resistance of between 0.4 and 2 (cm H2O)<1/2>SLM 13, which corresponds to a flow rate of 15 liters per minute or less. 2. The method of claim 1, wherein the initial target flow rate is maintained for less than 10 seconds. 3. The method of claim 1 or 2, wherein the flow resistance after said initial time period is over is reduced to a value corresponding to a flow rate of 15-80 liters per minute. 4. A device for delivering an aerosolized active agent to the lungs of a human patient, wherein comprising a flow resistance modulator of the aerosolized active agent formulation, which is adapted to produce the initial which is between 0.4 and 2 (cm H2O)<1/2>SLM.
The invention provides a prescription for treating eczema which is allergic dermatitis. The allergic dermatitis is characterized in itching, and symmetrically distributed with various shapes in general. Acute eczema is characterized in that skin itches and flushes at first, papula and vesicle occur immediately, skin extremely itches and is scratched, yellow fluid flows out, and yellow crusta is formed; eczema attacks repeatedly, cannot be cured for a long time, and is turned into chronic eczema; the skin is thickened, has wrinkles, rough, mild erosion with yellow fluid, and is itching; eczema mostly attacks on face and limbs, and is called eczema of scrotum if attacking on scrotum. Eczema often attacks on cheeks of children within 1-year old, and is called infantile eczema. The prescription is a creative traditional Chinese medical prescription for treating eczema prepared by years of repeatedly study and demonstration, conclusion by clinical specialized study and repeated practice on the base of curing multiple cases of patients. The prescription adopts pure traditional Chinese medicaments as raw materials, and is oral decoction for washing and applying by virtue of extraction of a traditional decoction method, acts appropriately to the situation according to the nosogenesis, does not have toxic or side effect, and has a unique treatment effect.
PURPOSE: To provide a medicinal compsn. for use in percutaneous administration, a matrix contg. such compsn. adsorbed thereon, a non-tacky adhesive and non- penetratable device for percutaneous administration of medicines to animals and a device for percutaneous administration of the medicines to man. CONSTITUTION: This medicinal compsn. contains at least components (1) and (2) among the arbitrary medicines selected from (1) an effective amt. of the medicines adapted to the percutaneous administration; (2) carriers (which are semi-solid and liquid at ambient temp. and contain at least one kind of the compds. selected from 8 to 24C ester of fatty acid, medicinally permissible fatty acid polyhydroxy compd. and non-volatile paraffin) for the medicines of the amt. effective for percutaneous transfusion and (3) antiphlogistics and histamine antagonists effective for relaxing any existing skin incompatible characteristics.
Paspalum L. is a genus of the Poaceae family, with many species serving as well-adapted forage plants in subtropical climates and continuous grazing systems. However, Claviceps paspali, an ascomycete of the order Hypocreales, represents a major threat to the Paspalum species. This fungus induces ergot disease, characterized by the replacement of infected flower seeds with sclerotia, which adversely affects seed production and animal health through mycotoxin production. Although ergot disease is reported in many countries, no totally resistant Paspalum cultivars have been reported for commercial use. This study comparatively evaluated disease development in six Paspalum species under greenhouse conditions with three specific isolates of C. paspali, along with field trials. In addition, field isolates of C. paspali were analyzed for phenotypic characteristics and phylogenetic relationships. Greenhouse evaluation revealed variable susceptibility among Paspalum species, with P. malacophyllum, P. notatum, and P. umbrosum being the most resistant. In field trials P. dilatatum showed the highest severity index, and P. umbrosum and P. malacophyllum were less affected. The phenotypic characterization of 22 C. paspali isolates showed variability in pigmentation and growth rates, with potato dextrose agar being the culture medium in which the highest growth rate was observed. Phylogenetic analysis of the isolates identified two well-supported lineages between C. paspali species. This research reports an ergot resistance gradient among Paspalum species, identifying genuine sources of resistance. In addition, virulent isolates of C. paspali potentially useful for rapid screening of accessions or crosses in Paspalum breeding programs were identified.[Formula: see text] Copyright © 2024 The Author(s). This is an open access article distributed under the CC BY-NC-ND 4.0 International license.
The present invention relates to a peptide having anti-inflammatory activity, which consists of any one of the amino acid sequences of SEQ ID NO. 2 to SEQ ID NO. 77. The invention also relates to polynucleotides encoding the peptides and the use of the peptides in the preparation of anti-inflammatory compositions. According to the present invention, the peptide has excellent efficacy in both inhibition of inflammation and prophylactic means. Thus, compositions comprising the peptides of the invention may be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions to treat or prevent a variety of different types of inflammatory diseases.
This invention relates to a kind of traditional Chinese medicinal composition, which has the therapeutic function of nephritis and uremia. It belongs to technical area of traditional Chinese medicine. The combination includes some raw material made by the following ratio of weight: Humulus scandens 2-8, Spora Lygodii 2-8, Serissa serissoides 5-15, Castanca seguinii 30-70, Phyllostachys nigra 5-15 and Lagenaria siceraria 2-8. The composition in this invention is made up of traditional Chinese medicine completely. It has non-toxic side effect and a high degree of therapeutic efficacy to acute or chronic nephritis and nephrasthenia, as well as uremia. It can effectively decompose and drainage blood myo-liver, the urea ammonia and the blood toxin. And it can also enhance and protect the kidney function. Take soup agent as an example; take orally two medicinal preparations in one day of the raw material medicine dosage of 250 grams and stick it out for three weeks as a course of treatment. It should take one to three courses of treatment for the nephritis and the uremia. The curative ratio can be up to 95.6%.
What should I avoid while taking Oral Transmucosal Fentanyl Citrate (OTFC)?   


  * Do not drive, operate heavy machinery, or do other dangerous activities until you know how OTFC affects how alert you are. OTFC can make you sleepy. Ask your doctor when it is okay to do these activities.
  * Do not drink alcohol while using OTFC. It can increase your chance of getting dangerous side effects.
  * Do not take any medicine while using OTFC until you have talked to your doctor. Your doctor will tell you if it is safe to take other medicines while you are using OTFC. Be especially careful about medicines that make you sleepy such as other pain medicines, anti-depressant medicines, sleeping pills, anxiety medicines, antihistamines, or tranquilizers.
The effects of sleep deprivation (SD) on performance, while contradictory at first glance, are in reality rather clear when exercise duration is considered, i.e. intense/supramaximal vs. prolonged exercises. This latter type of exercise leads to the most important performance decrements after SD. However, the causes of this accentuated fatigability in endurance exercise with sleep deficit are not known. Several hypotheses have been proposed such as lower pH before exercise, lower ventilation due to depreciated response to hypercapnia/hypoxia, or haemodilution. Yet the most plausible explanation is a lower tolerance to prolonged exercise because SD increases the rate of perceived exertion. Another potential effect of SD is an alteration of central command during exercise. The literature is rather scarce on this topic and is only based on a few animal studies. In humans, no effect of SD on maximal strength has been reported so that maximal voluntary activation should in theory not be altered. Transcranial Magnetic Stimulation (TMS), that allows to induce a motor response from its cortical origin (and to measure the resulting contraction), is a promising tool to explore neuromuscular function. TMS has been used only in three studies after SD, none of them involving exercise and none of them measuring mechanical responses (i.e. only EMG responses, such as motor evoked potential, were measured). In addition, the results of these three studies are contradictory. The effects of SD on central fatigue (i.e. increase of the activation deficit during exercise) have never been investigated. The goal of this experiment is thus to test the hypothesis that an increase in central fatigue (at supraspinal level) in SD can participate to performance alteration during a prolonged exercise. For that purpose, measurements of neuromuscular function particularly dedicated to assess central fatigue will be performed before and after SD but also when combining SD and a fatiguing exercise conducted until exhaustion.